Jul 20, 2023 9:58am EDT SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China
Jun 21, 2023 7:00am EDT SCYNEXIS Announces Achievement of First Development Milestone of $25 Million Under Exclusive License Agreement with GSK
May 12, 2023 8:00am EDT SCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets)
May 11, 2023 7:00am EDT SCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate Update
Apr 13, 2023 8:30am EDT SCYNEXIS to Present Ibrexafungerp Data at the 33rd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) April 15-18 in Denmark
Mar 31, 2023 8:30am EDT SCYNEXIS Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Mar 30, 2023 7:05am EDT GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection
Dec 01, 2022 8:00am EST SCYNEXIS Announces FDA Approval of Second Indication for BREXAFEMME® (ibrexafungerp tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis
Nov 30, 2022 8:30am EST SCYNEXIS Announces $3 Million National Institutes of Health Grant Has Been Awarded to Case Western Reserve University Researchers to Study Second Generation Fungerp (SCY-247) to Fight Drug-Resistant Fungi
